A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)

Recruiting

Phase 1

Phase 2

A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)

Sponsor:

AskBio Inc

Code:

NCT05230459

Conditions

Limb Girdle Muscular Dystrophy

Limb-Girdle Muscular Dystrophy Type 2

LGMD2I

Muscular Dystrophy

LGMD2

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

AB-1003 dose level 1

AB-1003 dose level 2

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-16. This information was provided to ClinicalTrials.gov by AskBio Inc on 2024-11-29.